BG101325A - Use of muramyl peptide compounds - Google Patents

Use of muramyl peptide compounds

Info

Publication number
BG101325A
BG101325A BG101325A BG10132597A BG101325A BG 101325 A BG101325 A BG 101325A BG 101325 A BG101325 A BG 101325A BG 10132597 A BG10132597 A BG 10132597A BG 101325 A BG101325 A BG 101325A
Authority
BG
Bulgaria
Prior art keywords
treatment
peptide compounds
muramyl
muramyl peptide
conditions
Prior art date
Application number
BG101325A
Other languages
Bulgarian (bg)
Inventor
Roger Aston
Y�Uri ��I����U�
���Y�N� �Ndr�N�V�
Original Assignee
Peptech (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptech (Uk) Limited filed Critical Peptech (Uk) Limited
Publication of BG101325A publication Critical patent/BG101325A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Certain muramul peptide derivatives such as GMDP findparticular use in the treatment of ophthalmic conditions such asherpetic keratitis and herpetic keratouveitis. The muramyl peptidederivatives are particularly useful for reducing or preventingcorneal scarring which may occur as a result of conditions such askeratitis. Treatment with muramyl peptide compounds may be used inaddition to treatment with other drugs.
BG101325A 1994-09-21 1997-03-13 Use of muramyl peptide compounds BG101325A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9419011A GB9419011D0 (en) 1994-09-21 1994-09-21 Use of muramyl peptide compounds
PCT/GB1995/002237 WO1996009063A1 (en) 1994-09-21 1995-09-20 Use of muramyl peptide compounds

Publications (1)

Publication Number Publication Date
BG101325A true BG101325A (en) 1998-01-30

Family

ID=10761674

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101325A BG101325A (en) 1994-09-21 1997-03-13 Use of muramyl peptide compounds

Country Status (13)

Country Link
EP (1) EP0782454A1 (en)
JP (1) JPH10506387A (en)
KR (1) KR970706015A (en)
AU (1) AU3527495A (en)
BG (1) BG101325A (en)
CA (1) CA2200570A1 (en)
CZ (1) CZ86197A3 (en)
GB (1) GB9419011D0 (en)
HU (1) HUT77741A (en)
IL (1) IL115391A0 (en)
SK (1) SK36697A3 (en)
WO (1) WO1996009063A1 (en)
ZA (1) ZA957997B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6693396A (en) * 1995-08-08 1997-03-05 Allergan, Inc. Method of increasing tear production by topical administration of muramyl peptide
DE10106852A1 (en) * 2001-02-14 2002-09-05 T Luger Anti-inflammatory compounds
CN108785251B (en) * 2018-01-23 2020-11-24 盛元医药广州有限公司 Medicinal composition for eyes and preparation method and application thereof
EP4308105A1 (en) 2021-03-19 2024-01-24 Trained Therapeutix Discovery, Inc. Compounds for regulating trained immunity, and their methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0026746B1 (en) * 1979-10-02 1985-04-10 Ciba-Geigy Ag Combinatory compositions for use in a method for enhancing the activity of antibiotics, antibiotic preparations having enhanced activity and process for their production
EP0056560A1 (en) * 1981-01-19 1982-07-28 Ciba-Geigy Ag Active antibiotic compositions, process for their manufacture and process for the antibiotic activity of antibiotics
EP0102319B1 (en) * 1982-07-23 1987-08-19 Ciba-Geigy Ag Prophylactic and therapeutic use of muramyl peptides and their analogues against viral infections
JPH04506808A (en) * 1989-07-19 1992-11-26 ジ・アップジョン・カンパニー Peptides containing diaminoglycols as transition state mimics
CA2123912C (en) * 1991-11-19 2007-04-17 Roger Aston Muramyl compounds for treatment of septic shock
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
MX9301789A (en) * 1992-04-03 1993-10-01 Iaf Biochem Int NEW LIPOPHILIC OLIGOPEPTIDES WITH IMMUNOMODULATING ACTIVITY.

Also Published As

Publication number Publication date
JPH10506387A (en) 1998-06-23
SK36697A3 (en) 1997-11-05
IL115391A0 (en) 1995-12-31
CZ86197A3 (en) 1997-08-13
EP0782454A1 (en) 1997-07-09
HUT77741A (en) 1998-07-28
KR970706015A (en) 1997-11-03
ZA957997B (en) 1997-03-24
WO1996009063A1 (en) 1996-03-28
CA2200570A1 (en) 1996-03-28
GB9419011D0 (en) 1994-11-09
AU3527495A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
LU90856I2 (en) Uprima - apomorphine hydrochloride and its pharmaceutically acceptable derivatives
BG100974A (en) Vaccines against papillomavirus
ATE280826T1 (en) CC CHEMOKINCEPTOR C-C CKR-5, DERIVATIVES THEREOF AND USES
GB9406857D0 (en) Improvements in or relating to organic compounds
GB9907461D0 (en) Neurite regeneration
PL319833A1 (en) Compounds and composition for carrying active media
BG95935A (en) METHOD AND AGENT FOR ADMINISTERING DEXMEDETOMIDINE DIRECTLY THROUGH THE SKIN
AU3380797A (en) Hypodermic injector system and method for maintaining the sterility thereof prior to use
UA41355C2 (en) Agent for treating neuro-aids
ZA965195B (en) 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents.
ES2134801T3 (en) CRYSTAL TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE.
AU2209500A (en) Inhibitors of alpha4beta1 mediated cell adhesion
CA2254682A1 (en) Method of treating eye infections with azithromycin
DE69311541D1 (en) COSMETIC OR PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE CONTAINING THE DEACYLATED GLYCEROPHOSPHOLIPIDES
SE9402880D0 (en) New peptide derivatives
BG101325A (en) Use of muramyl peptide compounds
MX9707875A (en) Levobupivacaine and its use as an anaesthetic in pregnant women.
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
EP0971725A4 (en) Methods for treatment of scar tissue
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
HU9600727D0 (en) Triaryl-ethylene derivatives for use in therapy
ES2170377T3 (en) COMPOSITION CONTAINING QUITOSANA.
TW340108B (en) 1,1-difluoro-1,4-dichlorobutane and process for its preparation